Nasdaq(NDAQ)
Search documents
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
GlobeNewswire News Room· 2024-10-07 11:05
Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development into 4Q25 Expanded pipeline includes a potential first-in-class non-opioid, NaV1.7 inhibition pain treatment, Halneuron®, currently in Phase 2b development for chemotherapy-induced neuropathic pain, with an expected interim readout 2H25Near-term catalyst with top-line results from the IMC-2 Long-COVID Phase 2a ...
Meihua International Medical Technologies Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement
Prnewswire· 2024-10-07 10:00
YANGZHOU, China, Oct. 7, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today announced that on October 3, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), informing the Company that it has regained compliance wi ...
Strong Performance by Nasdaq Golden Dragon China Index and Related ETFs
GuruFocus· 2024-10-06 04:10
During China's "Golden Week" holiday, overseas Chinese stocks and funds experienced notable gains. The Nasdaq Golden Dragon China Index increased by 3.1%, reaching its highest level since February 2, 2023, with a weekly gain of 11.9%.The iShares China Large-Cap ETF rose by 3.5%, marking its highest level since February 22, 2022, and recorded an 11% increase over the week. Similarly, the iShares MSCI China ETF advanced by 3.7%, hitting its highest point since March 2, 2022, with a weekly rise of 11.8%.The Kr ...
You'll Never Guess the Best-Performing Stock in the Nasdaq-100 Last Quarter. Is It Still a Buy?
The Motley Fool· 2024-10-05 11:39
Hint: It wasn't Nvidia.With the surge in tech stocks this year, it may be surprising that the best-performing stock in the tech-heavy Nasdaq-100 index last quarter wasn't a chipmaker or software company riding the artificial intelligence (AI) wave. It was PayPal (PYPL 2.65%).The stock of the fintech company surged 34.5% in the quarter, marking its best quarterly performance since 2020. The company's strong performance comes amid signs that the turnaround plan CEO Alex Chriss enacted is starting to take hold ...
Is It Time to Buy September's Worst-Performing Nasdaq Stocks?
The Motley Fool· 2024-10-05 08:00
September is typically a bad month for stocks, but the Nasdaq still gained.September has historically been the worst month of the year for the stock market with the S&P 500 falling on average during the month.However, this September bucked that trend with all three indexes posting positive gains. The Dow Jones Industrial Average and S&P 500 even hit all-time highs last month. As you can see, the Nasdaq Composite was the best-performing major index, rallying toward the end of the month after the Federal Rese ...
Urgently Notified By Nasdaq Of Non-Compliance With Nasdaq Minimum Bid Price Requirement
GlobeNewswire News Room· 2024-10-04 20:05
VIENNA, Va., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Urgent.ly Inc. (Nasdaq: ULY) (“Urgently”), a U.S.-based leading provider of digital roadside and mobility assistance technology and services, announced today that The Nasdaq Stock Market LLC (“Nasdaq”) notified Urgently (the “Notice”) that Urgently is not in compliance with Nasdaq’s Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) because the minimum bid price of Urgently’s common stock was below $1.00 per share for 30 consecutive business days. Th ...
Altamira Therapeutics Provides Update on Nasdaq Listing
GlobeNewswire News Room· 2024-10-04 20:01
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less th ...
Nasdaq Gains Over 100 Points; Beneficient Shares Spike Higher
Benzinga· 2024-10-04 18:32
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Friday.The Dow traded up 0.37% to 42,165.39 while the NASDAQ rose 0.77% to 18,056.62. The S&P 500 also rose, gaining, 0.46% to 5,726.34.Check This Out: How To Earn $500 A Month From Phillips 66 Stock Ahead Of Q3 EarningsLeading and Lagging SectorsFinancials shares jumped by 1.2% on Friday.In trading on Friday, real estate shares dipped by 0.9%.Top HeadlineThe total number of active U.S. oil rigs fe ...
Nasdaq Moves Lower; Levi Strauss Shares Slide
Benzinga· 2024-10-03 18:53
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday.The Dow traded down 0.54% to 41,969.72 while the NASDAQ fell 0.22% to 17,886.45. The S&P 500 also fell, dropping, 0.30% to 5,692.35.Check This Out: Wall Street’s Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend YieldsLeading and Lagging SectorsEnergy shares jumped by 1.3% on Thursday.In trading on Thursday, consumer discretionary shares dipped by 1.4%.Top Headl ...
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
GlobeNewswire News Room· 2024-10-02 22:35
IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc., one of the Company’s strategic partners. The gross proceeds to the Company from the private placement are expected to be approximately $10.2 million, before deducting the placement agent’s fe ...